Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Blood (2014) 123 (10): 1461–1469.

https://doi.org/10.1182/blood-2013-07-517276

Published: 2014

Journal Articles

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Blood (2013) 122 (21): 2.

https://doi.org/10.1182/blood.V122.21.2.2

Published: 2013

Journal Articles

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Abdullah Kutlar, MD, Paul S. Swerdlow, MD, Steffen E. Meiler, MD, Kavita Natrajan, MBBS, Leigh G Wells, MSN, RN, FNP-BC, Betsy Clair, Sheetal Shah, BA, Robert Knight, MD

Blood (2013) 122 (21): 777.

https://doi.org/10.1182/blood.V122.21.777.777

Published: 2013

Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2012) 120 (21): 2826.

https://doi.org/10.1182/blood.V120.21.2826.2826

Published: 2012

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Blood (2011) 118 (14): 3765–3776.

https://doi.org/10.1182/blood-2011-01-330126

Published: 2011

Includes: Supplemental data

Journal Articles

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Adrian Alegre, Albert Oriol-Rocafiguera, Jose García-Laraña, María-Victoria Mateos, Anna Sureda, MD, PhD, Carmen Martínez Chamorro, María Teresa Cibeira, MD, PhD, Robert Knight, MD, Barbara Rosettani

Blood (2010) 116 (21): 3045.

https://doi.org/10.1182/blood.V116.21.3045.3045

Published: 2010

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Peripheral Neuropathy In Multiple Myeloma Patients Treated with Lenalidomide

Carmen Castaneda, Lilia Weiss, Neil A. Minton, MD, MRCP, Alex Kim, John Freeman, Zhinuan Yu, Robert Knight, MD

Blood (2010) 116 (21): 5024.

https://doi.org/10.1182/blood.V116.21.5024.5024

Published: 2010

Journal Articles

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Blood (2010) 116 (5): 679–686.

https://doi.org/10.1182/blood-2010-02-268862

Published: 2010

Journal Articles

Risk Factors for Venous Thromboembolism and the Use of Antithrombotic Prophylaxis in Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone Combination Regimens.

Nancy A Brandenburg, Tyler Knight, Zdravko Vassilev, Robert Knight

Blood (2009) 114 (22): 1385.

https://doi.org/10.1182/blood.V114.22.1385.1385

Published: 2009

Journal Articles

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Blood (2009) 114 (22): 1218.

https://doi.org/10.1182/blood.V114.22.1218.1218

Published: 2009

Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD

Blood (2009) 114 (22): 3800.

https://doi.org/10.1182/blood.V114.22.3800.3800

Published: 2009

Journal Articles

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, M.D., Carlo Aul, Hans Kreipe, MD, Gudrun Goehring, Robert Knight, MD, John Francis, Tommy Fu, Eva Hellstrom-Lindberg, MD, PhD

Blood (2009) 114 (22): 944.

https://doi.org/10.1182/blood.V114.22.944.944

Published: 2009

Journal Articles

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

Kudrat M. Abdulkadyrov, M.D., Ph.D., Galina N. Salogub, M.D., Ph.D., Nuriet K. Khuazheva, M.D., Ph.D., Rachel Woolf, Eric Haltom, Niels G. Borgstein, MD, Robert Knight, MD, Gary Renshaw, DO, Yijun Yang, Matthew L. Sherman, MD

Blood (2009) 114 (22): 749.

https://doi.org/10.1182/blood.V114.22.749.749

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).

Lilia Weiss, MD, Kamal Shah, MD, Wai Yiu, PharmD, John Freeman, MSc., BSc., LLB, DipClinSci., Robert Knight, MD, Jerome B. Zeldis, MD

Blood (2009) 114 (22): 2881.

https://doi.org/10.1182/blood.V114.22.2881.2881

Published: 2009

Journal Articles

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Paul Richardson, Sundar Jagannath, Mohamad Hussein, James Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William Bensinger, Ashraf Z. Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight, Kenneth C. Anderson

Blood (2009) 114 (4): 772–778.

https://doi.org/10.1182/blood-2008-12-196238

Published: 2009

Journal Articles

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

Jean-Luc Harousseau, Donna Weber, Meletios Dimopoulos, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, David Siegel

Blood (2007) 110 (11): 3598.

https://doi.org/10.1182/blood.V110.11.3598.3598

Published: 2007

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

Blood (2007) 110 (11): 187.

https://doi.org/10.1182/blood.V110.11.187.187

Published: 2007

NARROW

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Peripheral Neuropathy In Multiple Myeloma Patients Treated with Lenalidomide

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Risk Factors for Venous Thromboembolism and the Use of Antithrombotic Prophylaxis in Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone Combination Regimens.

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Overview of Venous Thromboembolism (VTE) in Nearly 100,000 Patients Treated with Revlimid® (lenalidomide).

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only